Taysha Gene Therapies Net Income 2020-2026 | TSHA
Taysha Gene Therapies net income from 2020 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Taysha Gene Therapies Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-109 |
| 2024 | $-89 |
| 2023 | $-112 |
| 2022 | $-166 |
| 2021 | $-175 |
| 2020 | $-60 |
|
Taysha Gene Therapies Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-47 |
| 2026-03-31 | $-42 |
| 2025-12-31 | $-28 |
| 2025-09-30 | $-33 |
| 2025-06-30 | $-27 |
| 2025-03-31 | $-22 |
| 2024-12-31 | $-19 |
| 2024-09-30 | $-26 |
| 2024-06-30 | $-21 |
| 2024-03-31 | $-24 |
| 2023-12-31 | $48 |
| 2023-09-30 | $-117 |
| 2023-06-30 | $-25 |
| 2023-03-31 | $-18 |
| 2022-12-31 | $-55 |
| 2022-09-30 | $-27 |
| 2022-06-30 | $-34 |
| 2022-03-31 | $-50 |
| 2021-12-31 | $-50 |
| 2021-09-30 | $-51 |
| 2021-06-30 | $-41 |
| 2021-03-31 | $-32 |
| 2020-12-31 | $-18 |
| 2020-09-30 | $-15 |
| 2020-06-30 | $-21 |
| 2020-03-31 | $-5 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.652B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |